2 апр. 2024 г. · This study aimed to evaluate the risk of adverse events of special interest (AESI) following COVID-19 vaccination from 10 sites across eight countries.

The current COVID-19 pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2.

This paper provides an overview of the current SARS-CoV-2 vaccines with their mechanisms of action, current technologies utilized in manufacturing of the ...

10 апр. 2024 г. · Our recent study using data from more than 20 million participants has shown that COVID-19 vaccines consistently prevent long COVID symptoms ...

26 февр. 2024 г. · This study provided real-world evidence supporting the effectiveness of COVID-19 vaccines in reducing the risk of long-term health consequences of SARS-CoV-2 ...

Conclusions. All three Covid-19 vaccines had durable effectiveness in reducing the risks of hospitalization and death. Waning protection against infection over ...

Several COVID-19 vaccines have been developed and approved for emergency use. Current vaccines have shown efficacy with low risk of adverse effects.

27 февр. 2024 г. · To address this, our study aimed to investigate the adverse events (AEs) associated with different types and doses of COVID-19 vaccines across ...

19 мар. 2024 г. · We estimated vaccine effectiveness of mRNA COVID-19 vaccines in Medicare nursing home residents aged ≥65 years during pre-Delta and high Delta periods.

19 мая 2023 г. · After the first dose of the vaccine, the overall effectiveness of all COVID-19 vaccines was estimated to be 71% (95% CI 0.65, 0.78) (Fig. 2).